TY - JOUR
T1 - New targets and treatments in multiple myeloma
T2 - Src family kinases as central regulators of disease progression
AU - Gertz, Morie A.
N1 - Funding Information:
Editorial and writing support was provided by Gardiner-Caldwell US, funded by Bristol-Myers Squibb Company. M. Gertz has received honoraria for serving as a speaker for Celgene and Millenium.
PY - 2008
Y1 - 2008
N2 - Multiple myeloma is a malignant condition that most commonly occurs in the seventh decade of life. Recent improvements in treatment may result in a more favourable outlook for recently diagnosed patients. Multiple myeloma is an incurable clonal B-cell malignancy, which is initially responsive to conventional chemotherapy; one-third of the patients achieve complete remission but multidrug resistance eventually develops. Although autologous stem cell transplantation remains an important option, many older patients are less tolerant to the toxicity associated with conditioning treatment, as well as being intrinsically less likely to do well after transplantation. Most patients eventually relapse with or without transplantation, and salvage therapy is only moderately effective. Thalidomide and subsequently, lenalidomide and bortezomib, have demonstrated improved outcomes for these patients, as well as proving efficacious in front-line regimens. A deeper understanding of the molecular mechanisms underlying multiple myeloma has given rise to novel targeted approaches. This review will focus in particular on Src-dependent signalling pathways, reflecting the expanding realisation of the critical and ubiquitous role of Src family kinases (SFKs) in normal and abnormal hematopoiesis.
AB - Multiple myeloma is a malignant condition that most commonly occurs in the seventh decade of life. Recent improvements in treatment may result in a more favourable outlook for recently diagnosed patients. Multiple myeloma is an incurable clonal B-cell malignancy, which is initially responsive to conventional chemotherapy; one-third of the patients achieve complete remission but multidrug resistance eventually develops. Although autologous stem cell transplantation remains an important option, many older patients are less tolerant to the toxicity associated with conditioning treatment, as well as being intrinsically less likely to do well after transplantation. Most patients eventually relapse with or without transplantation, and salvage therapy is only moderately effective. Thalidomide and subsequently, lenalidomide and bortezomib, have demonstrated improved outcomes for these patients, as well as proving efficacious in front-line regimens. A deeper understanding of the molecular mechanisms underlying multiple myeloma has given rise to novel targeted approaches. This review will focus in particular on Src-dependent signalling pathways, reflecting the expanding realisation of the critical and ubiquitous role of Src family kinases (SFKs) in normal and abnormal hematopoiesis.
KW - Multiple myeloma
KW - Src family kinases
KW - Treatments
UR - http://www.scopus.com/inward/record.url?scp=57449115111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57449115111&partnerID=8YFLogxK
U2 - 10.1080/10428190802475311
DO - 10.1080/10428190802475311
M3 - Review article
C2 - 19052970
AN - SCOPUS:57449115111
SN - 1042-8194
VL - 49
SP - 2240
EP - 2245
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 12
ER -